Press release · 7 Nov 2026

Smart Inhalers Market Size, Share & Forecast 2026–2035

Published: 7 Nov 2026 | Forecast Coverage: 2026–2035 | Base Year: 2025 | Format: PDF | Publisher: Vectomat Insights

Author: Sneha ReddyReviewed by: Sunil BhosaleFact CheckedPublished:

Smart Inhalers Market by Product Type (Add-On Smart Inhalers, Integrated Smart Inhalers, Disposable Smart Inhalers), by Application (Asthma, COPD, Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions)), by Connectivity (Bluetooth-Enabled, Cellular-Enabled, NFC-Enabled), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End User (Homecare/Patients, Hospitals & Clinics, Others (Long-term care facilities, ambulatory surgical centers, and pharmacies)), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035

St. Catharines, Ontario, 7 Nov 2026 — Vectomat Insights has published a new report titled ‘Smart Inhalers Market by Product Type, Application, Connectivity, Distribution Channel, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Smart Inhalers market was valued at USD 1,246.7 Mn in 2025 and is projected to reach USD 3,934.7 Mn by 2035, growing at a CAGR of 12.18% during the forecast period 2026–2035, according to Vectomat Insights.

Add-on sensors that clip onto existing metered dose inhalers hold 54.0% of 2025 revenue, while integrated smart inhalers are the fastest-growing product type at a 16.17% CAGR, and North America leads with a 38.0% share.

The Global Smart Inhalers market was valued at USD 1,246.7 Mn in 2025 and is set to reach USD 3,934.7 Mn by 2035, a 12.18% CAGR over 2026–2035, according to Vectomat Insights. North America leads with 38.0% share. Add-on sensors such as Adherium's Hailie and Aptar's MDI sensor dominate product revenue at 54.0%, and asthma is the largest application.

Key Insights Snapshot

MetricValue
Report TitleGlobal Smart Inhalers Market Size, Share, Growth & Forecast By Product Type, Application, Connectivity, Distribution Channel, and End User, 2026–2035
Base Year Market SizeUSD 1,246.7 Mn (2025)
Forecast Market SizeUSD 3,934.7 Mn (2035)
CAGR12.18%
Forecast Period2026–2035
Dominant RegionNorth America (38.0%)
Fastest-Growing RegionAsia Pacific
Dominant SegmentAdd-On Smart Inhalers (54.0%)
Dominant ApplicationAsthma
Report FormatPDF
PublisherVectomat Insights

What Medical Device Leaders Need to Know About the Smart Inhalers Market

Medical Device Product Heads: Add-on sensors hold 54.0% of 2025 revenue, but integrated devices grow faster at 16.17% a year. Every inhaler being re-qualified for a low-carbon propellant is a chance to build the sensor in rather than bolt it on, and teams that miss that redesign window will wait years for the next one.

Hospital CIOs and CMOs: CMS's January 2026 codes (CPT 99445 and 99470) let practices bill remote monitoring with as few as 2 days of device data a month. Respiratory programs that couldn't hit the old 16-day threshold now pencil out, so budget for the data integration this cycle.

Regulatory Affairs Directors: Sensor clearances are drug-by-drug: Aptar's connected MDI sensor won FDA 510(k) clearance in October 2025, and Adherium needed separate clearances for each partner inhaler family. A device pipeline without a pharma co-development plan will stall at the label.

Healthcare Investors: Teva's 2024 exit from Digihaler shows that a connected inhaler without payer pull doesn't scale. The money is shifting to platform models with recurring revenue: Adherium reported record quarterly RPM revenue of A$479K in July 2026.

Payer and Managed Care Executives: Adherium's iCARE program reported US$12,943 in savings per monitored patient and 46% lower hospital costs in March 2026. Payers that wait for perfect evidence will keep paying for avoidable COPD admissions, each of which costs far more than a year of monitoring.

Smart inhalers market at a glance — USD 1,246.7 Mn (2025) to USD 3,934.7 Mn at 12.18% CAGR | Vectomat Insights
The Smart Inhalers market at a glance: USD 1,246.7 Mn in 2025, USD 3,934.7 Mn by 2035, North America leading and Asia Pacific growing fastest. Source: Vectomat Insights, Smart Inhalers Market Report.

What Is the Smart Inhalers Market?

Smart Inhalers Market refers to inhalers and clip-on sensors that record when, and increasingly how, a patient takes a dose, then send that record to a phone app or care team. Why now? Roughly half of people with asthma don't take controller medicine as prescribed, and payers have started paying for the data. CMS added two remote monitoring codes in January 2026, and Adherium reported that its iCARE program cut hospital costs by 46% for monitored patients. That's the business case in one line: fewer exacerbations, billed monitoring time. Vectomat Insights values the market at USD 1,246.7 Mn in 2025, rising to USD 3,934.7 Mn by 2035.

How Is the Smart Inhalers Market Segmented?

Add-on sensors own this market today. Add-On Smart Inhalers take 54.0% of 2025 revenue, USD 673.2 Mn, because a clip-on device like Adherium's Hailie works with the inhaler a patient already has. Integrated Smart Inhalers are the ones to watch: they're growing at 16.17% a year and could reach USD 1,785.8 Mn by 2035 as low-carbon inhaler redesigns let makers build sensors in. Asthma is the largest application at 56.0%, homecare patients account for 62.0% of end use, and Bluetooth carries 66.0% of device revenue. Retail pharmacies are the fastest-growing channel at 16.17%.

This report segments the Smart Inhalers market as follows:

  • By Product Type: Add-On Smart Inhalers, Integrated Smart Inhalers, Disposable Smart Inhalers
  • By Application: Asthma, COPD, Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions)
  • By Connectivity: Bluetooth-Enabled, Cellular-Enabled, NFC-Enabled
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • By End User: Homecare/Patients, Hospitals & Clinics, Others (Long-term care facilities, ambulatory surgical centers, and pharmacies)
  • By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa

Browse the full Smart Inhalers Market report →

Smart inhalers market size — USD 1,246.7 Mn (2025) to USD 3,934.7 Mn (2035) at 12.18% CAGR | Vectomat Insights
The Global Smart Inhalers market grows from USD 1,246.7 Mn in 2025 to USD 3,934.7 Mn by 2035, a 12.18% CAGR. Source: Vectomat Insights, Smart Inhalers Market Report.

Which Region Leads the Smart Inhalers Market?

North America runs this market, with 38.0% of 2025 revenue, or USD 473.7 Mn. The U.S. accounts for USD 369.5 Mn of that and is on course for roughly USD 1,049.2 Mn by 2035, helped by two new Medicare billing codes for remote monitoring that took effect in January 2026. Europe follows at 26.0%, led by Germany's USD 94.0 Mn market. Asia Pacific, at 24.0%, grows fastest: South Korea is expanding at 14.4% a year under a dedicated law for digital medical devices, and Japan at 12.5%. Latin America holds 5.0%, the Middle East 4.0% and Africa 3.0%.

Smart inhalers market share by region — North America leads with 38.0% in 2025 | Vectomat Insights
North America leads the Global Smart Inhalers market with a 38.0% share in 2025, followed by Europe at 26.0% and Asia Pacific, the fastest-growing region, at 24.0%. Source: Vectomat Insights, Smart Inhalers Market Report.

Smart Inhalers Market Growth Drivers

Medication Adherence Gap — About half of people with asthma skip controller doses, and smart inhalers make every missed dose visible. Adherium's iCARE program reported 46% lower hospital costs for monitored patients in March 2026.

New RPM Billing Codes — CMS's 2026 fee schedule lets U.S. practices bill remote monitoring with as few as 2 days of device data a month. That widens the pool of billable smart inhaler patients overnight.

Add-On Sensor Clearances — Aptar Digital Health won FDA 510(k) clearance for its connected MDI add-on in October 2025. More cleared sensors mean patients can keep the inhaler brands they already use.

The iCARE results show that when patients use Hailie sensors with remote monitoring, adherence to COPD and asthma medicines rises to levels clinicians rarely see in routine care.

— Dawn Bitz, Chief Executive Officer, Adherium · Press (paraphrased) · Adherium press release (iCARE study data), 15 Sep 2025 [source]

Smart Inhalers Market Challenges to Growth

Weak Uptake of Integrated Devices — Teva pulled its Digihaler range from the U.S. in 2024 and withdrew GoResp Digihaler in the UK. Integrated devices still cost more per fill and pay back slowly.

Data Privacy and Cybersecurity Burden — A connected inhaler is a regulated device that moves health data. FDA cybersecurity rules plus HIPAA and GDPR obligations stretch smaller developers' budgets.

Those headwinds slow adoption at the margins, but they don't change the trajectory from USD 1,246.7 Mn in 2025 to USD 3,934.7 Mn by 2035.

What Industry Leaders Are Saying About the Smart Inhalers Market

A next-generation Ventolin propellant can cut the carbon footprint of the inhaler by around 90% while giving patients the same medicine and the same experience.

— Tony Wood, Chief Scientific Officer, GSK · Press (paraphrased) · GSK press release (pivotal Phase III data, low carbon Ventolin), 22 Oct 2025 [source]

Discontinuing the Digihaler line means people with asthma who relied on it must switch devices, another disruption in care for patients who already face frequent inhaler changes.

— Kenneth Mendez, President and Chief Executive Officer, Asthma and Allergy Foundation of America · Press (paraphrased) · AAFA statement on Digihaler discontinuation, Apr 2024 [source]

Spending on digital health applications keeps growing, so their quality and their prices have to keep pace with the benefit they actually deliver to patients.

— Stefanie Stoff-Ahnis, Member of the Executive Board, GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) · Press (paraphrased) · GKV-Spitzenverband press release (DiGA report), 8 Apr 2026 [source]

Report Segmentation & Scope

Vectomat Insights | Market & Reports — Report Segmentation & Scope
Scope Included in the Study
By Product Type
  • Add-On Smart Inhalers
  • Integrated Smart Inhalers
  • Disposable Smart Inhalers
By Application
  • Asthma
  • COPD
  • Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions)
By Connectivity
  • Bluetooth-Enabled
  • Cellular-Enabled
  • NFC-Enabled
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By End User
  • Homecare/Patients
  • Hospitals & Clinics
  • Others (Long-term care facilities, ambulatory surgical centers, and pharmacies)
Regional Analysis
North AmericaThe U.S., Canada, Mexico
EuropeGermany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe
Asia PacificChina, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific
Latin AmericaBrazil, Argentina, Colombia, Chile, Peru, Rest of Latin America
The Middle EastGCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East
AfricaSouth Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa
Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com

Who Are the Leading Companies in the Smart Inhalers Market?

Key players operating in the Global Smart Inhalers market include Adherium (Australia), ResMed (Propeller Health) (United States), AptarGroup (Aptar Digital Health) (United States), Teva Pharmaceutical Industries (Israel), AstraZeneca (United Kingdom), GSK (United Kingdom), Chiesi Farmaceutici (Italy), Boehringer Ingelheim (Germany), Cipla (India), Lupin (India), Kindeva Drug Delivery (United States), and Bespak (United Kingdom), among others. It's a split field. Sensor specialists own the data layer, while pharma brand owners control which inhalers a sensor can be cleared against. That makes partnerships, not head-to-head share battles, the main competitive weapon, and the low-carbon propellant switch is reopening every device design.

Recent Developments in the Smart Inhalers Market

October 2025 — AptarGroup (Aptar Digital Health): Received FDA 510(k) clearance for its Sense device, a Class II connected add-on device for metered dose inhalers.

October 2025 — GSK: Reported positive pivotal Phase III data for a next-generation low-carbon Ventolin MDI using HFA-152a propellant.

March 2026 — Chiesi Farmaceutici: Expanded its partnership with Bespak to manufacture Carbon Minimal Inhalers at Holmes Chapel, UK.

April 2026 — AstraZeneca: Won FDA approval of Breztri Aerosphere for the maintenance treatment of asthma in patients aged 12 and older.

July 2026 — ResMed (Propeller Health): Agreed to sell its MatrixCare software business to Frazier Healthcare Partners for US$490 Mn to focus on sleep and connected care.

October 2026 — Adherium: Partnered with Florida Lung, Asthma & Sleep Specialists (FLASS) to expand Hailie remote monitoring into Central Florida.

Frequently Asked Questions

How big is the smart inhalers market?

The Global Smart Inhalers market was worth USD 1,246.7 Mn in 2025 and is forecast to reach USD 3,934.7 Mn by 2035, a compound annual growth rate of 12.18% over 2026–2035. Growth comes from connected sensors that record each inhaler dose, new U.S. billing codes for remote monitoring, and inhaler redesigns driven by low-carbon propellant rules in Europe, according to Vectomat Insights.

Which product type leads the smart inhalers market?

Add-on smart inhalers lead with 54.0% of 2025 revenue, or USD 673.2 Mn. A clip-on sensor such as Adherium's Hailie or Aptar Digital Health's MDI add-on turns an inhaler the patient already uses into a connected device, with no new drug filing. Integrated smart inhalers are smaller at 32.0% but grow fastest, at 16.17% a year through 2035, according to Vectomat Insights.

Which region dominates the smart inhalers market?

North America holds the largest share at 38.0% of 2025 revenue, worth USD 473.7 Mn, and the U.S. alone accounts for USD 369.5 Mn. U.S. payers reimburse remote monitoring, and the FDA has cleared several add-on sensors. Asia Pacific, with 24.0% of revenue, is the fastest-growing region, with South Korea expanding at 14.4% a year and Japan at 12.5%, according to Vectomat Insights.

What is driving smart inhaler adoption?

Three forces stand out. About half of people with asthma skip controller doses, and sensors make that visible to clinicians. CMS's 2026 fee schedule lets U.S. practices bill monitoring with only 2 to 15 days of device data a month. And more sensors are cleared, including Aptar Digital Health's MDI add-on in October 2025, so patients can keep their usual inhaler brands, according to Vectomat Insights.

Who are the leading companies in the smart inhalers market?

Key companies include Adherium, ResMed (Propeller Health), AptarGroup (Aptar Digital Health), Teva Pharmaceutical Industries, AstraZeneca, GSK, Chiesi Farmaceutici, Boehringer Ingelheim, Cipla, Lupin, Kindeva Drug Delivery and Bespak. Sensor specialists run the data platforms, while pharma brand owners and contract manufacturers control the inhalers sensors must fit, so most growth comes through partnerships between the two groups rather than head-to-head competition, according to Vectomat Insights.

How can I access the full VMI Smart Inhalers market report?

The full report runs to 300+ pages with 118 tables and 86 figures, covering five segment dimensions, 35+ countries and 12 company profiles. You can request a free sample or buy the full report on the Vectomat Insights website, or email sales@vectomatinsights.com with your questions or to discuss customization of up to 10% of the scope, according to Vectomat Insights.

Access the Complete Smart Inhalers Market Report

300+ pages | Global coverage | PDF | 2026

Contact: sales@vectomatinsights.com

About Vectomat Insights

Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.

Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312